SynthesisBMC oral health2025
Use of platelet-rich plasma (PRP) and injectable platelet-rich fibrin (i-PRF) in oral lichen planus treatment: a systematic review of randomized controlled trials.
Synthesis in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Multiple-Site Lichen Planus: An Italian Case Series of 44 Patients.Journal of clinical medicine · 2025Article
- Platelet-Rich Concentrates in the Management of Lichen Planus-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Application of Platelet-Rich Fibrin and Concentrated Growth Factors as Carriers for Antifungal Drugs-In Vitro Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLichen planus (LP) is a chronic inflammatory disease that affects the skin and mucous membranes, including the oral cavity. The prevalence of oral lichen planus (OLP) in the general population is estimated to be between 0.5% and 2%, with a higher incidence observed in women aged between 30 and 80 years. The etiology of OLP remains unclear, which presents a significant challenge in terms of diagnosis and treatment. This systematic review assessed the efficacy of platelet-rich plasma (PRP) and injectable platelet-rich fibrin (i-PRF) in the treatment of OLP.
methodsA comprehensive literature search was conducted via multiple databases in accordance with the PRISMA 2020 guidelines.
resultsA total of seven randomized controlled trials were subjected to analysis. It has been demonstrated that both PRP and i-PRF have the capacity to significantly improve clinical outcomes, including pain and lesion severity. However, the majority of studies have not demonstrated statistically significant differences between PRP/i-PRF and corticosteroid treatments.
conclusionsWhile PRP and i-PRF demonstrate potential in alleviating symptoms and promoting tissue healing, their effectiveness appears to be analogous to that of corticosteroids in the majority of RCTs. Further high-quality, standardized studies are required to substantiate their function as alternative or adjunctive therapies in the management of OLP.
trial registrationThis systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) on 28 November 2024 (PROSPERO 2024 CRD42024615291).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.